Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Adjunctive MK-1167 in Mild to Moderate Alzheimer's Disease Dementia
jRCT2031240682Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-1167 in Alzheimer's disease (AD) (4 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in the ADAS-Cog11 Total Score at Week 24, Number of participants who experience one or more adverse events and 1 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
MK-1167
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031240682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240682.